'Awakening': A confusing improvement during treatment with atypical antipsychotic agents;'Awakening': Een verwarrende verbetering tijdens behandeling met atypische antipsychotica

Nederlands Tijdschrift voor Geneeskunde

Volumn 149, Issue 31, 2005, Pages 1717-1720

  Vergouwen, A C M ^a   De Bruijn, C ^a,b   Been, A ^a  

^a ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^b UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE;

ADULT; AROUSAL; ARTICLE; CASE REPORT; CLINICAL FEATURE; EMOTION; FEMALE; FOLLOW UP; HUMAN; RECURRENT DISEASE; SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; COGNITION; FEMALE; HUMANS; PIPERAZINES; QUALITY OF LIFE; QUINOLONES; RISPERIDONE; SCHIZOPHRENIA; TREATMENT OUTCOME;

EID: 23844486792     PISSN: 00282162     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (9)

1. Herz MI, Marder SR. Schizophrenia. Comprehensive treatment and management. Philadelphia: Lippincott Williams & Wilkins; 2002.
2. Harvey PD, Green MF, Keefe RSE, Velligan DI. Cognitive functioning in schizophrenia: a consensus statement on its role in the definition and evaluation of effective treatments for the illness. J Clin Psychiatry 2004;65:361-72.
3. American Psychiatric Association (APA). Diagnostic and statistical manual of mental disorders. 4th ed. Washington: APA; 1994.
4. Duckworth K, Nair V, Patel JK, Goldfinger SM. Lost time, found hope and sorrow: the search for self, connection, and purpose during 'awakenings' on the new antipsychotics. Harv Rev Psychiatry 1997;5: 227-33.
5. Sacks O. Awakenings. New York: Harper; 1990.
6. Lindström LH. Long-term clinical and social outcome studies in schizophrenia in relation to the cognitive and emotional side effects of antipsychotic drugs. Acta Psychiatr Scand Suppl 1994;380:74-6.
7. Stahl SM. 'Awakening' from schizophrenia: intramolecular polypharmacy and the atypical antipsychotics. J Clin Psychiatry 1997;58: 381-2.
8. Weiden P, Aquila R, Standard J. Atypical antipsychotic drugs and long-term outcome in schizophrenia. J Clin Psychiatry 1996;57 Suppl 11:53-60.
9. Bourgeois M, Swendsen J, Young F, Amador X, Pini S, Cassano GB, et al. Awareness of disorder and suicide risk in the treatment of schizophrenia: results of the international suicide prevention trial. Am J Psychiatry 2004;161:1494-6.